D
Diagonal Therapeutics
Diagonal Therapeutics leads in pioneering a fresh method for discovering and advancing agonist antibodies in biotechnology
About Diagonal Therapeutics
Diagonal Therapeutics is a biotechnology company focused on developing innovative agonist antibody therapeutics to treat the underlying causes of debilitating diseases. The company leverages a proprietary platform to create multispecific antibodies, allowing for 10 billion possible combinations, which helps in selecting the best clinical candidates. Diagonal Therapeutics operates in the biopharmaceutical market, primarily serving patients with severe medical conditions that lack effective treatments. The business model revolves around research and development, with revenue generated through partnerships, licensing agreements, and eventual commercialization of successful therapies. The company is led by a team of experienced scientific and business leaders, including CEO Alex, who has a robust background in biotechnology and drug discovery. Diagonal Therapeutics aims to transform patient outcomes by reactivating critical biological pathways.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Watertown, United States
- Employees
- 31
- Open positions
- 2
- Dealroom signal
- 82.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2026 | $125M | $500M | Atlas Venture · Viking Global Investors · Paulina Hill · Logos Capital | ↗ |
| SERIES AOther financing | Apr 2024 | $128M | $512M | Lightspeed Venture Partners · RA Capital Management · Velosity Capital · Checkpoint Capital | ↗ |
Growth signals
Latest recorded traffic for Diagonal Therapeutics is 4.6K monthly website visits, down 14.8% over the last three months. Diagonal Therapeutics's team grew 10.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A18 investors entered at this stage
Atlas Venture
BVF Partners
Lightspeed Venture Partners
RA Capital Management
Velosity Capital
Checkpoint Capital
Frazier Life Sciences
Viking Global Investors
Janus Henderson Investors
Sanofi Ventures- PHPaulina Hill
Logos Capital
Biovision Ventures
Balyasny Asset Management
EcoR1 Capital
Woodline Partners
Deep Track Capital
RV Invest
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Diagonal Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Diagonal Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.